JP2019510064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510064A5 JP2019510064A5 JP2018551333A JP2018551333A JP2019510064A5 JP 2019510064 A5 JP2019510064 A5 JP 2019510064A5 JP 2018551333 A JP2018551333 A JP 2018551333A JP 2018551333 A JP2018551333 A JP 2018551333A JP 2019510064 A5 JP2019510064 A5 JP 2019510064A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- hepatitis
- hbv
- use according
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700721 Hepatitis B virus Species 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 229920002477 rna polymer Polymers 0.000 claims 6
- 101710132601 Capsid protein Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000002672 hepatitis B Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 206010042566 Superinfection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016-0038 | 2016-03-31 | ||
| CU2016000038A CU24454B1 (es) | 2016-03-31 | 2017-03-14 | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
| PCT/CU2017/050001 WO2017167317A1 (es) | 2016-03-31 | 2017-03-14 | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510064A JP2019510064A (ja) | 2019-04-11 |
| JP2019510064A5 true JP2019510064A5 (enExample) | 2020-04-23 |
| JP6981992B2 JP6981992B2 (ja) | 2021-12-17 |
Family
ID=58671308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551333A Active JP6981992B2 (ja) | 2016-03-31 | 2017-03-14 | Ｂ型肝炎ウイルスの表面及び核内抗原を含む医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11491218B2 (enExample) |
| EP (1) | EP3437654B1 (enExample) |
| JP (1) | JP6981992B2 (enExample) |
| KR (1) | KR20180125985A (enExample) |
| CN (1) | CN109219449B (enExample) |
| AR (1) | AR108009A1 (enExample) |
| AU (1) | AU2017243136B2 (enExample) |
| BR (1) | BR112018069738A2 (enExample) |
| CA (1) | CA3017778A1 (enExample) |
| CU (1) | CU24454B1 (enExample) |
| EA (1) | EA201892212A1 (enExample) |
| ES (1) | ES2965709T3 (enExample) |
| MX (1) | MX2018011793A (enExample) |
| MY (1) | MY202118A (enExample) |
| TW (1) | TWI755383B (enExample) |
| UA (1) | UA128952C2 (enExample) |
| WO (1) | WO2017167317A1 (enExample) |
| ZA (1) | ZA201806325B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020355020A1 (en) * | 2019-09-23 | 2022-04-28 | Ascendo Biotechnology, Inc. | Biodegradable nanocomplex vaccines, methods for suppression of hepapitis B virus replication and hepapitis B virus surface antigen secretion |
| CU20200028A7 (es) | 2020-04-20 | 2021-11-04 | Ct Ingenieria Genetica Biotecnologia | Nucleoproteína viral y formulaciones que la contienen |
| CN116218881B (zh) * | 2022-10-21 | 2024-08-13 | 山东大学 | 一种治疗或者预防乙肝病毒的疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22290A1 (es) | 1990-10-08 | 1995-01-31 | Cigb | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
| CU22871A1 (es) | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
| CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| CN1164331C (zh) * | 2001-05-23 | 2004-09-01 | 中国人民解放军第二军医大学 | 一种人乙型肝炎核酸疫苗 |
| CU23740A1 (es) | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
| CN110859961A (zh) * | 2013-07-26 | 2020-03-06 | 复旦大学 | 病毒免疫治疗药物复合物在制备治疗hbv感染药物中的应用 |
-
2017
- 2017-03-14 EP EP17721509.2A patent/EP3437654B1/en active Active
- 2017-03-14 CN CN201780033618.XA patent/CN109219449B/zh active Active
- 2017-03-14 EA EA201892212A patent/EA201892212A1/ru unknown
- 2017-03-14 UA UAA201810715A patent/UA128952C2/uk unknown
- 2017-03-14 JP JP2018551333A patent/JP6981992B2/ja active Active
- 2017-03-14 AU AU2017243136A patent/AU2017243136B2/en not_active Ceased
- 2017-03-14 ES ES17721509T patent/ES2965709T3/es active Active
- 2017-03-14 WO PCT/CU2017/050001 patent/WO2017167317A1/es not_active Ceased
- 2017-03-14 MY MYPI2018703588A patent/MY202118A/en unknown
- 2017-03-14 US US16/088,188 patent/US11491218B2/en active Active
- 2017-03-14 CU CU2016000038A patent/CU24454B1/es unknown
- 2017-03-14 MX MX2018011793A patent/MX2018011793A/es unknown
- 2017-03-14 KR KR1020187028749A patent/KR20180125985A/ko not_active Ceased
- 2017-03-14 CA CA3017778A patent/CA3017778A1/en active Pending
- 2017-03-14 BR BR112018069738A patent/BR112018069738A2/pt active Search and Examination
- 2017-03-22 TW TW106109533A patent/TWI755383B/zh not_active IP Right Cessation
- 2017-03-30 AR ARP170100786A patent/AR108009A1/es not_active Application Discontinuation
-
2018
- 2018-09-20 ZA ZA2018/06325A patent/ZA201806325B/en unknown
-
2022
- 2022-03-08 US US17/689,581 patent/US11759517B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526596A5 (enExample) | ||
| JP2018523668A5 (enExample) | ||
| JP2009539965A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| JP2019511542A5 (enExample) | ||
| JP2013241424A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2013522302A5 (enExample) | ||
| JP2015096557A5 (enExample) | ||
| ME02893B (me) | Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina | |
| JP2015528449A5 (enExample) | ||
| JP2016531144A5 (enExample) | ||
| JP2017512789A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| JP2019510064A5 (enExample) | ||
| JP2019505553A5 (enExample) | ||
| Noordeen | Hepatitis B virus infection: An insight into infection outcomes and recent treatment options | |
| US11759517B2 (en) | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus | |
| Ponde et al. | Elimination of the hepatitis B virus: A goal, a challenge | |
| JP2009518410A5 (enExample) | ||
| JP2020536098A5 (enExample) | ||
| JP2016520077A5 (enExample) |